[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pregnant-women\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pregnant-women":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,50,81,109,131,159,189,214,235,260,287,314,339,365,389,413,435,460,480,506,533,558,591,614,644],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100624727","oral-health-education-for-pregnant-women-100624727",false,"NCT07413393","Oral Health Education for Pregnant Women","Knowledge of Oral Health in Pregnant Women: Effect of a Short Educational Intervention","Inclusion Criteria:\n\n* Women aged 18-45 who have recently given birth to healthy babies, either vaginally or by cesarean section.\n* Ability to understand and speak Spanish.\n\nExclusion Criteria:\n\n* Complications during pregnancy or delivery.\n* Newborns with major birth defects.\n* Participants who do not provide informed consent.","FEMALE","18 Years","45 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this research is to investigate oral health knowledge in pregnant women receiving care at Hospital La Fe and to see whether a one-time informational intervention improves this knowledge. The main questions this research aims to answer are:\n\nWhat is the level of oral health knowledge among pregnant women attending Hospital La Fe?\n\nDoes a one-time informational intervention, delivered through a printed leaflet, improve oral health knowledge during pregnancy?\n\nWhat factors are related to differences in oral health knowledge among pregnant women?\n\nParticipants are pregnant women receiving care at Hospital La Fe. They will:\n\nComplete a questionnaire about their oral health knowledge.\n\nReceive a printed informational leaflet about oral health during pregnancy.\n\nComplete the same questionnaire again after a period of time to see if their knowledge has changed.\n\nResearchers will compare answers before and after the leaflet is provided to see whether oral health knowledge improves. They will also explore which personal or social factors are linked to different levels of oral health knowledge.",[28,29,30,31],"Knowledge","Oral Health","Pregnant Women","Intervention",[33,34,35,36],"oral health","knowledge","pregnant","improvement","RECRUITING","2026-06-05",{"date":40,"type":41},"2026-06-09","ACTUAL",{"date":43,"type":41},"2026-02-15",{"date":45,"type":22},"2026-07-30",{"name":47,"class":48},"University of Valencia","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100436511","neuraxial-labor-analgesia-and-offspring-neurodevelopment-100436511","NCT04964206","Neuraxial Labor Analgesia and Offspring Neurodevelopment","Impact of Maternal Neuraxial Labor Analgesia on Offspring Neurodevelopment. A Multicenter, Prospective, Longitudinal Cohort Study","Inclusion Criteria:\n\n1. Primiparae between 18 and 35 years of age with term single cephalic pregnancy;\n2. Undergo regular prenatal examination in the study centers;\n3. Preparing to deliver vaginally.\n\nExclusion Criteria:\n\n1. History of psychiatric diseases (indicate those that are diagnosed before or during pregnancy by psychiatrists);\n2. History of diseases involving the hypothalamic-pituitary-adrenal axis;\n3. Presence of contraindications to epidural analgesia, which includes: (1) History of infectious disease of the central nervous system (poliomyelitis, cerebrospinal meningitis, encephalitis, etc.); (2) History of spinal or intra-spinal disease (trauma or surgery of spinal column, intra-spinal canal mass, etc.); (3) Systemic infection (sepsis); (4) Skin or soft tissue infection at the site of epidural puncture; (5) Coagulopathy.\n4. Presence of contraindications to vaginal delivery;\n5. Other reasons that are considered unsuitable for study participation.","35 Years",{"count":59,"type":22},4645,"24 Months","OBSERVATIONAL","How perinatal factors affect the long-term development of children has always been an issue of much concern. This study is designed to explore the potential impact of maternal neuraxial labor analgesia exposure on offspring neurodevelopment.",[30,64,65,66,67],"Labor Pain","Analgesia, Epidural","Infants","Neurodevelopmental Disorders",[69,70,71,66,72],"Pregnant women","Labor pain","Neuraxial labour analgesia","Neurodevelopmental disorders",{"date":40,"type":41},{"date":75,"type":41},"2022-10-14",{"date":77,"type":22},"2028-12",{"name":79,"class":48},"Dong-Xin Wang",2,{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":80},"100560297","thrombinography-in-pregnant-woman-and-in-vitro-action-of-low-molecular-weight-heparin-100560297","NCT06575309","THROmbinography in Pregnant Woman and in Vitro Action of Low Molecular Weight HEparin","Longitudinal Study of the in Vitro Action of Low Molecular Weight Heparin (LMWH) in Pregnant Women by Thrombinography","TROPHE","Inclusion Criteria:\n\n* Normal 1st trimester pregnancy\n* Age \\> 18\n\nExclusion Criteria:\n\n* Coagulation disease (Von Willebrand disease, known coagulation factor deficiency before pregnancy)\n* VTE history\n* First-degree family history of idiopathic VTE\n* Known biological risk factor for thrombosis Inherited deficiencies in coagulation inhibitors (antithrombin, protein C, protein S) Factor V Leiden polymorphism Prothrombin gene 20210G\\>A polymorphism Anti-phospholipid antibodies\n* Current anticoagulant use (VKA, heparins, etc.)\n* Gestational diabetes detected in the 1st trimester\n* Pre-existing type 1 and type 2 diabetes\n* History of pathological pregnancy Premature delivery Postpartum hemorrhage Preeclampsia\n* Hepatopathy\n* Obesity (BMI ≥ 30)\n* Infections (HIV, HBV, HCV...)\n* Autoimmune diseases\n* Pregnancy resulting from in vitro fertilization protocol\n* Multiple pregnancy\n* Patient under guardianship, curatorship or safeguard of justice\n* Patient not covered by a social security scheme\n* Patient deprived of liberty","55 Years",{"count":91,"type":22},50,"Pregnancy is associated with major changes affecting all satges of hemostasis. Certain procoagulant factors are increased, such as factors VII, VIII, IX, X, XII, fibrinogen and Von Willebrand factor. Anticoagulant molecules are also affected by pregnancy, notably the protein C - protein S (PC - PS) system. overall, PC activity is little affected by pregnancy, increasing in the 2nd trimester and decreasing in the 3rd, but remaining within normal values. PS decreases from the first trimester of pregnancy, then progressively with gestational age. Antithrombin is stable during pregnancy.\n\nThe increased in most coagulation factors, combined with the decrease in concentrations of anticoagulant molecules, creates a state of relative hypercoagulability that protects women from bleeding during homostatic challenge of childbirth, but predisposes them to venous thromboembolic events.\n\nThe risk of venous thromboembolism (VTE) during pregnancy is increased compared to non-pregnant women of the same age. The post-partum period is also considered a thrombotic risk state for up to 12 weeks after delivery. Data on the incidence of VTE as a function of gestational age are contradictory: depending on the study, incidence may be stable or increase with advancing pregnancy.\n\nLow-molecular-weight heparin (LMWH) is the anticoagulant treatment of choice for prophylactic or curative treatment of VTE during pregnancy.\n\nPhysiological changes during pregnancy may alter the pharmacokinetic properties of LMWH. The increased volume of distribution and higher glomerular filtration rate may result in a reduced anticoagulant effect. On the other hand, the state of hypercoagulability probably counteracts the anticoagulant effect of LMWH. Nevertheless, the need to adjust doses during pregnancy remains controversial, and monitoring of anti-Xa activity is not clearly recommended. The optimal dose of LMWH in pregnant women, for both preventive and curative treatment, remains poorly understood. Initiation of treatment with LMWH therefore requires discussion of the dosage to be administered.\n\nAssessment of anticoagulation using more precise tools than those currently available on a routine basis could be useful in this context.\n\nThrombinography enables the amount of thrombin generated in the presence of coagulation activators to be assessed over time. This tool can be used to assess the impact of in vitro addition of different doses of LMWH in pregnant versus non-pregnant women and in the postpartum period.\n\nIn this pilot study, the investigators propose to evaluate thrombin generation, before and after in vitro addition of LMWH, in pregnant women longitudinally, during the 3 trimesters of pregnancy, postpartum and post-pregnancy.",[30,94],"Venous Thromboembolic Disease",[96,97,98,99],"Thrombography","Pregnancy","Postpartum","Low molecular weight heparins (LMWH)","2026-05-28",{"date":102,"type":41},"2026-05-29",{"date":104,"type":41},"2024-11-22",{"date":106,"type":22},"2027-12",{"name":108,"class":48},"University Hospital, Clermont-Ferrand",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":49},"100466829","testing-effects-of-melatonin-on-uterine-contractions-in-women-100466829","NCT05358834","Testing Effects of Melatonin on Uterine Contractions in Women","MelPreg","Inclusion Criteria:\n\n* nulliparity, age between 18 and 35,\n* BMI\\\u003C36 pre-pregnancy,\n* ≥38 weeks of pregnancy with a single fetus at time of study.\n\nExclusion Criteria:\n\n* color blind;\n* prescription drugs affecting sleep, melatonin, and\u002For circadian rhythms (e.g., beta blockers, non-steroidal anti-inflammatory drugs);\n* a health or pregnancy related condition that might affect melatonin or uterine contractions;\n* medical conditions or medications for which melatonin might be contraindicated or there may be a drug interactions (e.g., Central Nervous System depressants\u002Fsedatives, Fluvoxamin (Luvox), medications for diabetes, immunosuppressants, anti-coagulants, Nifedipine, Verapamil).\n\nNote: We cannot list all possible exclusionary criteria. Dr. Carolina Bibbo (co-I), our Obstetrics Investigator at Brigham and Women's Hospital (BWH), will make final determination of suitability including any safety concerns for each potential participant.",true,{"count":118,"type":22},120,[25],"The study will extend recent discoveries that have been made in basic human physiology related to responses melatonin and uterine contractions in late- or full-term pregnant women. The basic physiology work has been conducted in in vitro models of the human myometrium characterizing its responses to melatonin, and in pilot in vivo studies correlating the number of uterine contractions with melatonin concentrations that were manipulated by different types of light exposure. The planned experiments will test a causal link between circulating melatonin levels and uterine contractions in full-term pregnant women by manipulating melatonin levels using exogenous melatonin (i) during the day when endogenous levels of melatonin are very low (Experiment 1), and (ii) during the evening under conditions with lighting that would be expected to suppress the higher evening and nighttime levels of endogenous melatonin (Experiment 2).",[30],"2026-05-14",{"date":124,"type":41},"2026-05-18",{"date":126,"type":41},"2023-01-01",{"date":128,"type":22},"2027-06-30",{"name":130,"class":48},"Brigham and Women's Hospital",{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":49},"100640737","a-research-comparing-efficacy-of-pieb-plus-pcea-vs-cei-plus-pcea-for-labour-analgesia-100640737","NCT07592364","A Research Comparing Efficacy of PIEB Plus PCEA vs CEI Plus PCEA for Labour Analgesia","A Randomized Controlled Trial Comparing Efficacy of Programmed Intermittent Epidural Bolus (PIEB) Plus Patient-Controlled Epidural Analgesia (PCEA) Versus Continuous Epidural Infusion (CEI) Plus Patient-Controlled Epidural Analgesia (PCEA) for Labour Analgesia","Inclusion Criteria:\n\n* All pregnant female \\> 36 weeks of gestation\n* Age 18 years old and above\n* ASA I and II\n* Consented for study\n\nExclusion Criteria:\n\n* Allergies to LA and opioids\n* Severe systemic and mental disease\n* Contraindication to regional analgesia\n* Hemodynamic instabilities\n* Systemic coagulopathies\n* Treatment with anticoagulants\n* Severe obstetric complications - eg. eclampsia, placenta previae\n* Patient refusal\n* Failed epidural insertion",{"count":139,"type":22},88,[25],"During labour process, one of the most effective ways to manage pain is via epidural analgesia. It is commonly and widely use for all pregnant women underwent labour process. It provides good pain relief during labour process especially for contraction pain and pain during descending of baby during delivery.\n\nDuring epidural insertion, a small catheter (which is flexible and thin) will be inserted via epidural needle at the back. Using this epidural catheter, pain medication will be given to ease and help controlling the pain. This procedure is usually done after you have been admitted to labour room.\n\nIn this research, investigator will compare among two different method of epidural administration which are:\n\n\\- Programmed Intermittent Epidural Bolus with Patient-Controlled Epidural Analgesia (PIEB +\n\nPCEA):\n\n* This method will enable the medication to be served automatically within the set time through the epidural catheter and allows for participants to manage additional boluses of medication according to the participants pain level.\n\n  \\- Continuous Epidural Infusion with Patient-Controlled Epidural Analgesia (CEI + PCEA):\n* This method will deliver continuous infusion of medication and allows for participants to manage additional boluses of medication according to the participants pain level.\n\nInvestigator want to determine the best method between this two in order to have better pain control, less usage of medication and improving the satisfaction of patient. In participating this research, the participants will help us in understanding the best method to be use for the labour process in which eventually help other future patient who is in need.",[30,143],"Labour Analgesia",[145,146,147,148,149,143],"Parturient","Pregnant","PIEB","PCEA","CEI","NOT_YET_RECRUITING","2026-05-13",{"date":124,"type":41},{"date":154,"type":22},"2026-07-01",{"date":156,"type":22},"2027-12-31",{"name":158,"class":48},"Aiman Bin Ab Adzim",{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":116,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":175,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":49},"100637653","prenatal-yoga-intervention-in-pregnant-women-100637653","NCT07585916","Prenatal Yoga Intervention in Pregnant Women","Effects of a Prenatal Yoga Intervention on Traumatic Childbirth Perception, Self-Perception, and Delivery Preferences in Pregnant Women","Inclusion Criteria:\n\n* Being at or beyond the 16th week of gestation (second trimester or later)\n* Being aged 18 years or older\n* Having no diagnosis of high-risk pregnancy based on obstetric evaluation\n* Having no medical restriction on physical activity or yoga practice as determined by a physician\n* Providing written informed consent after being informed about the study\n\nExclusion Criteria:\n\n* Diagnosis of high-risk pregnancy (e.g., preeclampsia, placenta previa, premature rupture of membranes, risk of preterm birth, or other serious obstetric complications)\n* Physician-imposed restriction on physical activity\n* Presence of serious systemic conditions that would prevent participation in yoga practice\n* Inability to complete the questionnaires reliably due to psychiatric or cognitive conditions\n* Declining to participate or not providing informed consent",{"count":167,"type":22},46,[25],"The aim of this study is to determine the effects of a prenatal yoga intervention on traumatic childbirth perception, self-perception, and delivery preferences in pregnant women.",[30,171,172,173,174],"Prenatal Yoga","Trauma","Body Image","Delivery",[176,177,178,179,180],"perception of traumatic childbirth","body image","preferred mode of delivery","pregnant women","prenatal yoga","2026-05-09",{"date":122,"type":41},{"date":184,"type":22},"2026-05-15",{"date":186,"type":22},"2026-12-30",{"name":188,"class":48},"Saglik Bilimleri Universitesi",{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":80},"100613356","outpatient-induction-of-labour-using-a-double-balloon-transcervical-catheter-in-low-risk-pregnant-women-a-two-centre-open-prospective-randomised-controlled-trial---outcrib-100613356","NCT07265518","Outpatient Induction of Labour Using a Double Balloon Transcervical Catheter in Low-risk Pregnant Women: a Two-centre Open Prospective Randomised Controlled Trial - OutCRIB","OutCRIB","Inclusion Criteria:\n\n* Pregnant woman with singleton pregnancy in cephalic presentation\n* Term ≥ 37SA+0d\n* Age ≥ 18 years\n* Affiliated or beneficiary of a social security scheme\n* No severe maternal\u002Fneonatal pathology (severe pre-eclampsia, intra-uterine growth retardation, etc.)\n* Indication for balloon induction\n* Bishop score \\\u003C6\n* Home-hospital distance ≤ 30 minutes' drive\n* Presence of a family member at the woman's side to help her return home\n\nExclusion Criteria:\n\n* Scarred uterus\n* Fetal heart rhythm abnormalities\n* Rupture of membranes\n* Death in utero\n* Placenta previa or adherent placenta (accreta or percreta)\n* Maternal respiratory, cardiac, hepatic, renal, digestive or decompensated psychiatric pathology\n* Anamnios\n* Patient under guardianship, curatorship and\u002For safeguard of justice",{"count":197,"type":22},258,[25],"The aim goal of this study is to compare the duration of induction and labor between outpatient and inpatient care in low-risk pregnant women.\n\nThe secondary objectives are to compare between the two groups the maternal satisfaction from induction to delivery, the maternal and neonatal morbidity and mortality, impact on service organization and a medico-economic evaluation (cost-consequence analysis) from a collective perspective and with a time horizon of one month For women who do not agree to take part in the randomized study, an observational study will be proposed to them in order to collect the reason for their refusal and their maternal satisfaction.\n\nResearchers will compare the return home with conventional hospitalization\n\nPatients presenting with a singleton pregnancy and with an indication for induction of labor will be proposed to participate in the study.\n\nIf the pregnant woman refuses to participate in the randomized study, she will be invited to take part in the observational study.\n\nFor women who accept, a fetal heart rate recording (FHRR) is made prior to balloon insertion. If there is no fetal heart rhythm abnormality (FHR), the double balloon catheter is inserted by a midwife. A further ERCF is performed to ensure that the procedure is well tolerated.\n\nIn the absence of metrorrhagia, fetal heart rate abnormalities, rupture of the water sac or uterine hypertonia\u002Fhyperkinesia, the patient will then be randomized to either the in-patient or out-patient arm. The patient will either be placed in a room or go home.\n\nIn both cases, the balloon will be removed after 24 hours in hospital in the absence of spontaneous labor, and the patient will be referred to the delivery room for water breakage and\u002For oxytocin infusion for induction.",[30],[202,203,204],"outpatient labor induction","low-risk pregnant women","transcervical catheter","2026-05-06",{"date":207,"type":41},"2026-05-07",{"date":209,"type":41},"2026-04-30",{"date":211,"type":22},"2028-01-15",{"name":213,"class":48},"Nantes University Hospital",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":232,"locationsCount":4},"100636522","cell-based-non-invasive-prenatal-test-workflow-100636522","NCT07566780","Cell-based Non-invasive Prenatal Test Workflow","Prospective Collection of Maternal Venous Blood Samples for Cell-based Non- Invasive Prenatal Test Workflow","TOTAL#5","Inclusion Criteria:\n\n1. Informed consent signed before any study-specific procedures\n2. Pregnant women with singleton or twin pregnancy, at 8+0 - 14+6 week of gestation, aged ≥18 years\n3. No medical contraindication for collecting 30 ml blood sample\n\nExclusion Criteria:\n\n1. Unable to provide informed consent\n2. Known infections that carry a risk of vertical transmission\n3. Known maternal viral diseases: HIV and HCV, HBV",{"count":223,"type":22},1400,"The aim of this study is to optimize a new non-invasive prenatal screening method based on the capture of fetal cells from maternal blood and to complete its development by obtaining maternal blood samples during the first trimester of pregnancy.",[30],"2026-04-28",{"date":228,"type":41},"2026-05-05",{"date":230,"type":22},"2026-05-04",{"date":156,"type":22},{"name":233,"class":234},"Menarini Silicon Biosystems","INDUSTRY",{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":49},"100473567","phase-3-prenatal-treatment-of-congenital-cytomegalovirus-infection-with-letermovir-versus-valaciclovir-100473567","NCT05446571","Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir","Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir (Step 2)","CYMEVAL3-step2","Inclusion Criteria:\n\n* Pregnant woman ≥ 18 years old,\n* CMV infection in the 1st trimester\n* with an infected fetus at 15 -28 weeks (positive CMV PCR in the amniotic fluid) With a fetus presenting without any severe cerebral ultrasound feature (ventriculomegaly ≥15 mm, hydrocephalus, periventricular hyperechogenicity, microcephaly\\\u003C-3SD, vermian hypoplasia, porencephaly, lissencephaly, corpus callosum dysgenesis, cystic leukomalacia)\n* affiliation to a social security regime\u002F\u002Fhealth insurance\n* Given consent for the study\n* Patient must be able and willing to comply with study visits and procedures\n\nExclusion Criteria\n\n* Participation to another interventional drug trial (category 1)\n* Subject protected by law under guardianship or curatorship\n* Maternal CMV infection after 15 weeks'\n* Creatinine clearance \\\u003C50 ml\u002Fmn\u002F1,73m²\n* Liver insufficiency (Child Pugh grade C), AST, ALT 5 x ULN, bilirubin 2 x ULN.\n* Woman with known allergy to Letermovir or Valaciclovir\n* Contraindication for the administration of Letermovir and Valaciclovir listed in the SmPC of Prevymis® and Zelitrex®\n* Women with hypersensitivity to aciclovir\n* Concomitant administration of St John's wort\n* Woman treated by pimozide, ergot alkaloids, dabigatran, atorvastatin, simvastatin, rosuvastatin, pitavastatin or cyclosporin.\n* Woman with hereditary intolerance to galactose, with lactose lapp deficiency, glucose or galactose malabsorption syndrome",{"count":167,"type":22},[245],"PHASE3","The investigators' hypothesis is that maternal treatment with Letermovir will inhibit fetal CMV replication better than Valaciclovir in infected fetuses and lead to a higher proportion of negative CMV PCR at birth in neonatal blood collected in the first day of life or in cord blood in case of termination of pregnancy (TOP).\n\nThe main objective is to demonstrate that Letermovir administered to women carrying a CMV infected fetus following a maternal infection of the first trimester increases the proportion of neonates with a negative CMV PCR in neonatal blood collected in the first day of life or in cord blood in case of termination of pregnancy (TOP) compared to Valaciclovir.\n\nIn each group , the proportion of asymptomatic neonates and the number and type of long-term sequelae at 2 years will also be assessed and compared.",[30,248],"CMV Infected Fetuses",[250,179],"cytomegalovirus","2026-03-26",{"date":253,"type":41},"2026-03-31",{"date":255,"type":41},"2023-10-20",{"date":257,"type":22},"2029-08",{"name":259,"class":48},"Assistance Publique - Hôpitaux de Paris",{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":116,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":268,"targetDuration":4,"studyType":23,"phases":270,"briefSummary":271,"conditions":272,"keywords":273,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":4},"100631239","the-effect-of-haptonomy-practice-on-pregnant-women-with-a-history-of-abortion-100631239","NCT07498088","THE EFFECT OF HAPTONOMY PRACTICE ON PREGNANT WOMEN WITH A HISTORY OF ABORTION.","THE EFFECT OF HAPTOTHERAPY APPLİCATİON ON PRE-NATAL ATTACHMENT AND ANXİETY LEVELS İN PREG-NANT WOMEN WİTH A HİSTORY OF ABORTİON","Haptonomy","Inclusion Criteria:\n\n* Primiparous pregnant women with a history of abortion\n* Singleton pregnant women with a healthy pregnancy between 28 and 32 weeks\n* Women who conceived naturally\n* Pregnant women without psychiatric disorders\n* Pregnant women without a diagnosed genetic disease\n* Pregnant women without a history of two or more abortions\n\nExclusion Criteria:\n\n* Pregnant women diagnosed with high-risk pregnancies during the study\n* Pregnant women who were included in the study but could not be reached\n* Pregnant women who did not continue with the treatment during the study",{"count":269,"type":22},80,[25],"Pregnancy is a period of comprehensive adaptation for a woman in physiological, psychological, and social terms. During this process, physical and mental transformations occur due to hormonal changes; multifaceted changes emerge, such as adopting the role of motherhood, developing a new sense of identity, and adapting to increased responsibilities. These changes during pregnancy affect not only the mother but also the fetus. Especially from the 26th week of pregnancy onwards, with the development of the fetus's auditory and sensory perception capacity, a process of reciprocal interaction begins between mother and fetus. This early interaction forms the basis of prenatal bonding.Prenatal bonding is a dynamic process involving behaviors such as the mother developing emotional closeness towards the fetus, talking to it, making contact, and preparing for care. This bonding directly affects the post-natal mother-baby relationship. However, prenatal bonding is influenced by many factors such as anxiety, stress, history of psychiatric illness, pregnancy complications, socioeconomic status, social support, and previous pregnancy experiences. Women who have experienced prenatal loss (abortion, stillbirth, neonatal death) frequently experience increased anxiety, stress, and difficulty bonding in subsequent pregnancies. High levels of uncertainty, fear, and anxiety in these individuals can negatively impact both the pregnancy and postpartum periods. The literature indicates that women who have experienced prenatal loss have lower levels of prenatal bonding and increased risks of anxiety and depression compared to those who have had healthy pregnancies. Increased stress and anxiety during the prenatal period have also been shown to be associated with negative outcomes such as low birth weight, premature birth, and neurodevelopmental problems. Therefore, supporting psychological well-being during pregnancy is critically important.In this context, interventions aimed at strengthening the bond between mother and fetus are gaining importance. Haptonomy, as a touch-based approach, is a holistic method that supports the establishment of emotional bonds between mother, father, and fetus. This method aims to develop trust-based communication by prioritizing the physical and emotional acceptance of the individual's presence. In haptonomy practices, the goal is for expectant mothers to first increase their own bodily and emotional awareness, and then to establish a conscious interaction with the fetus. Studies show that haptonomy reduces stress, anxiety, and fear of childbirth in pregnant women, while increasing prenatal bonding levels. It is also reported to have positive effects on newborns, improving their adaptation to environmental stimuli. However, the number of studies on haptonomy is limited, and research is needed, particularly focusing on its effects in pregnant women who have experienced prenatal loss. The aim of this research is to examine the effect of haptonomy on prenatal bonding and anxiety levels in pregnant women who have experienced abortion. It is hypothesized that haptonomy may strengthen mother-fetus bonding by reducing negative emotions experienced during pregnancy after a loss. The findings are expected to contribute to evidence-based care approaches applicable to high-risk pregnancy groups.",[30],[274,275,276,277],"haptonomy","abortion","anxiety","attachment","2026-03-23",{"date":280,"type":41},"2026-03-27",{"date":282,"type":22},"2026-03-30",{"date":284,"type":22},"2026-08-28",{"name":286,"class":48},"Uskudar University",{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":23,"phases":297,"briefSummary":298,"conditions":299,"keywords":300,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":312,"locationsCount":49},"100591146","effect-of-helfer-skin-tap-and-cold-application-on-pain-and-hemodynamics-during-vaccination-100591146","NCT06976632","Effect of Helfer Skin Tap and Cold Application on Pain and Hemodynamics During Vaccination","Comparison of the Effects of the Helfer Skin Tap Technique and Local Cold Application on Pain and Hemodynamic Parameters During Vaccination in Pregnant Women","Inclusion Criteria: Pregnant women who meet the following criteria will be included in the study:\n\n* Over the age of 18,\n* Scheduled to receive a tetanus vaccine,\n* Able to speak and communicate in Turkish,\n* Willing to participate in the study,\n* Not experiencing any pain for any reason prior to the injection.\n\nExclusion Criteria: Pregnant women who meet any of the following criteria will be excluded from the study:\n\n* Under the age of 18,\n* Received a tetanus vaccine for reasons other than pregnancy,\n* Received a vaccine other than tetanus,\n* Experiencing pain for any reason prior to the vaccine,\n* Have circulatory disorders or peripheral vascular disease,\n* Have bleeding or clotting disorders,\n* Have a local infection,\n* Used painkillers at least 6 hours prior to the procedure,\n* Underwent a painful procedure within the last hour,\n* Have cold sensitivity,\n* Have cognitive or psychological issues.","42 Years",{"count":296,"type":22},90,[25],"The purpose of this study is to investigate the effect of local cold application using the Helfer Skin Tap Technique on pain levels during the intramuscular injection of the tetanus vaccine in pregnant women. The study will also record vital signs, which are among the physiological effects of pain.",[30],[301,302,303,179,304,305],"immunization","pain","hemodynamic parameters","local cold application","helfer skin tap tecnique","2026-03-18",{"date":308,"type":41},"2026-03-20",{"date":310,"type":41},"2025-05-09",{"date":40,"type":22},{"name":313,"class":48},"Celal Bayar University",{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":116,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":322,"conditions":323,"keywords":324,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":49},"100556318","ultra-early-identification-of-fetal-chromosomal-characteristics-from-extravillous-trophoblast-cells-100556318","NCT06523543","Ultra-early Identification of Fetal Chromosomal Characteristics From Extravillous-trophoblast Cells","CellF-Cervix","Inclusion Criteria:\n\n* Pregnant woman\n* Singleton pregnancy\n* Pregnancy between 7 and 16 weeks of amenorrhea (WA)\n* Woman ≥ 18 years\n* Woman who has signed an informed consent\n* Woman affiliated to social security or equivalent scheme\n\nExclusions Criteria:\n\n* Person under guardianship or curatorship\n* Person placed under legal protection\n* Person unable to provide the participant with informed consent.",{"count":7,"type":22},"Demonstrate the efficacy of an ultra-early, non-invasive prenatal diagnostic method adaptable to various genetic indications to detect fetal chromosomal abnormalities.",[30],[325,326,327,328,329],"Trophoblast cells","Endocervical canal","Fluorescent in situ hybridization (FISH)","Non-invasive prenatal test","Fetal gender","2026-03-12",{"date":332,"type":41},"2026-03-13",{"date":334,"type":41},"2024-11-19",{"date":336,"type":22},"2028-09-01",{"name":338,"class":48},"University Hospital, Montpellier",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":347,"targetDuration":349,"studyType":61,"phases":4,"briefSummary":350,"conditions":351,"keywords":353,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":49},"100628914","prevention-of-stretch-marks-in-expectant-mothers-100628914","NCT07467837","Prevention of Stretch Marks in Expectant Mothers","Prevention (Reduction of Incidence) of Stretch Marks in Expectant Mothers","PRIME","Inclusion Criteria:\n\n* Pregnant women at any gestational age.\n* Participants who are in good health, including those that are carrying multiples, who are 18 years of age or older.\n* Confirmed absence of pre-existing stretch marks on the abdomen.\n* Agree to apply Stratamark according to the prescribed protocol for the duration of the study.\n* Ability to complete remote online surveys via an electronic device.\n* Provide signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Visible stretch marks on the abdomen prior to enrollment.\n* Pre-existing skin conditions (e.g., eczema, psoriasis), on the abdomen that could interfere with product application or assessment of stretch marks.\n* Known hypersensitivity or allergy to any of the ingredients in Stratamark.\n* Use of other topical treatments on the abdomen, including but not limited to oils, or creams targeting stretch mark prevention.\n* Participants unable to give informed consent, or unable to have written consent provided on their behalf.\n* Participants who cannot administer the treatment or have the treatments administered as per the directions for use.",{"count":348,"type":22},10000,"30 Weeks","PRIME Mothers is a national observational trial designed to evaluate patient outcomes with Stratamark® for the prevention of stretch marks during pregnancy and the postpartum period. The study is designed to fit seamlessly into routine clinical practice, with digital follow-up and home resupply, minimising clinic involvement.",[30,352],"Stretch Mark",[354,355,356],"Stratamark","expectant mothers","prevention of stretch marks","2026-03-11",{"date":330,"type":41},{"date":360,"type":41},"2026-02-24",{"date":362,"type":22},"2027-02",{"name":364,"class":234},"Stratpharma AG",{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":23,"phases":375,"briefSummary":376,"conditions":377,"keywords":379,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":80},"100543567","evaluation-of-the-absence-of-intraoperative-bladder-catheterization-in-case-of-planned-cesarean-section-100543567","NCT06357546","Evaluation of the Absence of Intraoperative Bladder Catheterization in Case of Planned Cesarean Section","Evaluation of the Absence of Intraoperative Bladder Catheterization in Case of Planned Cesarean Section: Multicenter Non-inferiority Randomized Controlled Trial","C2S","Inclusion Criteria:\n\n* Adult patient\n* Patient admitted for a planned cesarean section after 34 weeks under spinal anesthesia\n* Single or twin pregnancy\n* Unscarred or with one or two scars of the uterus\n\nExclusion Criteria:\n\n* Positive urine test strip showing a presence of nitrites or leukocytes, the day before the surgery suggesting asymptomatic bacteriuria\n* Emergency Caesarean\n* Scheduled Caesarean section with intervention delayed beyond 3 p.m. for service organization reasons\n* Epidural anesthesia\n* Contraindication to spinal anesthesia (uncorrected hypovolemia; blood coagulation disorders; sepsis or severe inflammation at the puncture site; neurological deficit; migraine pattern; spinal cord disease; spinal malformation; febrile syndrome)\n* ASA (American Society of Anesthesiologists) score ≥ 4\n* Placental insertion abnormality (placenta previa and\u002For accreta)\n* Medical indication for monitoring of diuresis\n* Oliguria or renal failure\n* Indication for use of intrathecal clonidine during scheduled cesarean section\n* History of bladder surgery or surgical urological pathology during pregnancy (JJ catheter in place)\n* History of complex abdominal surgery\n* Impossibility or absence of obtaining free, informed and written consent, after a period of reflection\n* Patient not affiliated or beneficiary of a national health insurance system\n* Patient under legal protection, under guardianship or under curatorship\n* Patient having participated in interventional research on a drug within 3 months before inclusion\n* Patient participating in another interventional research\n* Patient in exclusion period determined by another study",{"count":374,"type":22},550,[25],"The hypothesis of this trial is that the absence of systematic bladder catheterization in patients performing spontaneous urination in the hour preceding the planned cesarean section under spinal anesthesia would not lead to more bladder heterocatheterization for postpartum urinary retention (RUPP) in the 24 hours post-cesarean section than systematic intraoperative bladder catheterization up to 2 hours post-surgery.",[30,378],"Cesarean Section",[380,378,381],"Catheterization Urethral","Postpartum Urinary Retention","2026-03-10",{"date":330,"type":41},{"date":385,"type":41},"2025-01-20",{"date":387,"type":22},"2029-11",{"name":338,"class":48},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":396,"targetDuration":397,"studyType":61,"phases":4,"briefSummary":398,"conditions":399,"keywords":402,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":4},"100618711","gastric-ultrasound-before-elective-cesarean-section-100618711","NCT07335172","Gastric Ultrasound Before Elective Cesarean Section","Bedside Gastric Ultrasound Before Elective Cesarean Section: Observational Study","Inclusion Criteria:\n\n* Aged 18-45 years\n* Term pregnant women classified as ASA II scheduled for elective cesarean section\n* Those who voluntarily agree to participate in the study\n\nExclusion Criteria:\n\n* Cases requiring emergency (Lucas classification based on the urgency of caesarean section, Category 1-2)\n* Multiple pregnancies",{"count":269,"type":22},"2 Days","Due to the physiologically delayed gastric emptying in pregnant women, the potential risk of aspiration before cesarean delivery constitutes an important source of perioperative complications, and when it occurs, it is associated with increased maternal morbidity and\u002For mortality. Systematic reviews and meta-analyses have demonstrated that, compared with non-pregnant women, gastric emptying is delayed particularly during the first trimester of pregnancy, and that gastric emptying does not occur in cases who have consumed solid food within the last 8 hours and in whom labor has begun.\n\nThis study aims to evaluate preoperative gastric volumes by ultrasonography in ASA II pregnant women (according to the American Society of Anesthesiologists classification, healthy parturients without complications) scheduled to undergo elective cesarean delivery under general or spinal anesthesia, based on different fasting durations for solid and liquid intake, with the type of liquid.\n\nAlthough previous research in pregnant populations has predominantly focused on the importance of gastric ultrasonography in the presence of gestational diabetes mellitus, this thesis study aims to generate data from the general population. The findings are expected to enable individualized preventive measures to reduce aspiration-related complications during cesarean deliveries performed under general or spinal anesthesia, thereby contributing to patient safety.",[400,401,30],"Gastric Ultrasound","Elective Cesarean Section",[400,403],"elective cesarean section","2026-01-05",{"date":406,"type":41},"2026-01-13",{"date":408,"type":22},"2026-01",{"date":410,"type":22},"2026-04",{"name":412,"class":48},"Ekin Deniz KUTLU",{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":420,"maxAge":421,"enrollmentInfo":422,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":432,"locationsCount":434},"100498886","association-of-gestational-cardiovascular-health-with-pregnancy-outcomes-100498886","NCT05776082","Association of Gestational Cardiovascular Health With Pregnancy Outcomes","Association of Cardiovascular Health During Pregnancy With Perinatal Outcomes---a Birth Cohort Study","Inclusion Criteria:\n\n* Maternal age: 20-49 years;\n* Natural conception;\n* Single pregnancy;\n* Plan to have routine prenatal examinations and give birth in the research center;\n\nExclusion Criteria:\n\n* Have diseases that affect metabolic function or even threaten the life of the mother and fetus before pregnancy;\n* Assisted reproduction;\n* Multiple pregnancy;\n* Fetus has a known deformity or genetic defects;\n* Incomplete clinical data.","20 Years","49 Years",{"count":423,"type":22},5000,"Pregnancy is a critical period for cardiovascular health risk assessment and interventions to reduce the incidence of cardiovascular disease in both mother and child generations. Recently, the American Heart Association proposed the latest cardiovascular health assessment indicator \"Life's Essential 8\". However, there is still a lack of application data for pregnant women. This project intends to explore the application potential of Life's Essential 8 in cardiovascular health assessment of pregnant women and establish appropriate gestaional cardiovascular health standards.",[30],"2025-12-21",{"date":428,"type":41},"2025-12-29",{"date":430,"type":41},"2023-03-01",{"date":156,"type":22},{"name":433,"class":48},"Women's Hospital School Of Medicine Zhejiang University",3,{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":116,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":23,"phases":444,"briefSummary":445,"conditions":446,"keywords":448,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":49},"100616828","impact-of-mhealth-education-on-hemoglobin-level-among-pregnant-women-with-anemia-in-rural-bangladesh-100616828","NCT07310680","Impact of mHealth Education on Hemoglobin Level Among Pregnant Women With Anemia in Rural Bangladesh.","Mobile Health","Inclusion Criteria:\n\n\\- 1. Pregnant women who will be diagnosed with mild and moderate anemia (Blood hemoglobin levels are between 7g\u002FdL and 10.9 g\u002FdL).\n\n2\\. Have at least one active mobile phone in the family. 3. Those who will give written informed consent to participate in the intervention study at the time of enrollment\n\nExclusion Criteria:\n\n\\- 1. Hospitalized at the time of the study period. 2. Women with any known or suspected chronic or congenital disease, such as blood inflammation, diabetic mellitus, thalassemia, hypertension, and psychiatric illness.\n\n3\\. Those who have severe anemia. 4. Having the possibility of leaving the study area during this study period.",{"count":443,"type":22},132,[25],"Anemia in pregnancy can result in negative pregnancy outcomes, which are higher among pregnant women of rural Bangladesh. A cost-effective health education program is urgently needed to introduce, which will help to improve their hemoglobin level by changing their lifestyle. In many rural settings, mobile-based health (mHealth) education programs have been shown to improve hemoglobin levels effectively during the antenatal period. So, we aim to assess the impact of a mHealth education program on improving hemoglobin levels among anemic pregnant women of rural Bangladesh.\n\nThe study will be carried out in the rural settings of a district of Bangladesh named Chandpur. This study timeline is from December 2025 to May 2026.\n\nAfter this survey, a randomized controlled trial study will be conducted where 160 pregnant women who are diagnosed with mild and moderate anemia will be offered to participate. Pregnant women who will give informed consent will be randomly assigned to two arms: intervention and control. Every arm will have an equal number of anemic pregnant women. Pregnant women in the intervention arm will receive anemia management-related health education through mobile messages and calls. This intervention program will educate pregnant women about the causes, risks, and symptoms of anemia, with the prevention strategies like dietary improvement, supplementation, parasitic disease control, safe motherhood, family planning, and iron-rich food production. Additionally, they will get regular care, a booklet and reminders of ANC visits during the study period. In contrast, the pregnant women of the control arm will receive regular care during this period, but after the end-line assessment, they will also get the booklet. After 4 months of the intervention program, the end-line assessment will be done, where the hemoglobin, nutritional status, and literacy about anemia will be assessed. Multiple comparisons will be performed by two-way analysis of variance tests for the evaluation of the outcome variables. Additionally, a Generalized Estimating Equations (GEE) model will be used to analyze the effect of the mHealth education program on related factors. A p-value less than 0.5 will be considered significant in this study.\n\nIf this mHealth-based education program shows improvement in hemoglobin level, this can be utilized in low-resource settings widely to ensure safe pregnancy outcomes in the future.",[447,30],"Anemia",[447,69,449,450],"mHealth","Bangladesh","2025-12-20",{"date":453,"type":41},"2025-12-30",{"date":455,"type":22},"2026-02-01",{"date":457,"type":22},"2026-10-31",{"name":459,"class":48},"Hiroshima University",{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":80},"100612803","screening-for-intrapartum-fetal-compromise-using-placental-biomarkers-100612803","NCT07258329","Screening for Intrapartum Fetal Compromise Using Placental Biomarkers","Screening Della Compromissione Fetale Intrapartum Mediante Utilizzo Dei Marcatori Placentari","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Gestational age ≥ 32 weeks\n* Obtaining informed consent for participation in the study and for the processing of personal data\n* Pregnant patients with an indication to perform placental marker testing as part of routine clinical practice\n* Patients who will deliver at the Obstetrics Units of the participating centers\n\nExclusion Criteria:\n\n\\- Absolute contraindications to vaginal delivery (placenta previa, vasa previa, placenta accreta, previous myomectomy)",{"count":468,"type":22},428,"This study aims to investigate the association between placental markers (sFlt-1, PlGF, and the sFlt-1\u002FPlGF ratio) and intrapartum fetal compromise, assessed on the basis of the cardiotocographic tracing.",[30],"2025-11-26",{"date":473,"type":41},"2025-12-02",{"date":475,"type":41},"2025-03-28",{"date":477,"type":22},"2028-10-01",{"name":479,"class":48},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":488,"targetDuration":490,"studyType":61,"phases":4,"briefSummary":491,"conditions":492,"keywords":493,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":49},"100611286","impact-of-ufps-and-mnps-on-fetal-health-100611286","NCT07238608","Impact of UFPs and MNPs on Fetal Health","UPRISE Unravelling Ultrafine Particulate Matter and Micro Nano Plastic's Mechanisms of Impact on Fetal Health","UPRISE","Inclusion Criteria:\n\n* Agreement to sign the informed consent;\n* Non-smoking mothers and no exposure to environmental (second-hand) smoke (smoking influences UFP measurements);\n* ≥18 years old (mothers have to place sensors, mothers with childhood pregnancies may live at their parental home);\n* Not expecting to terminate the pregnancy (no measurements of the child);\n* Having resided in the geographical area of research for a minimum period of 1 year (to be eligible for modeling exposures).\n\nExclusion Criteria:\n\n* First visit after 11 weeks of gestation (to ensure 2-week monitoring in the first trimester);\n* Pregnancy complications that limit exposure measurements in urine (because it may cause polyuria, for example, gestational diabetes);\n* Known kidney disease (might influence exposure measurements in urine);\n* Multiple pregnancy (twin or more pregnancies may have a higher risk for complications or preterm birth, no measurements in the last trimester).",{"count":489,"type":22},1600,"5 Years","This project aims at unravelling mechanisms by which exposure to air pollution (in particular Ultrafine Particulate (UFP, PM0.1), and micro nano plastic's) interferes with the normal foetus development, with a short-term causal effect in higher likeliness of preterm delivery which, in consequence, precondition a higher likeliness to suffer non-communicable diseases (NCD) later in the life.",[30],[494,495,496],"non-communicable diseases","Ultrafine Particulate","micro nano plastics","2025-11-15",{"date":499,"type":41},"2025-11-20",{"date":501,"type":22},"2026-01-01",{"date":503,"type":22},"2029-12-31",{"name":505,"class":48},"Instituto de Investigacion Sanitaria La Fe",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":116,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":512,"targetDuration":513,"studyType":61,"phases":4,"briefSummary":514,"conditions":515,"keywords":517,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":49},"100151717","national-pregnancy-registry-for-psychiatric-medications-100151717","NCT01246765","National Pregnancy Registry for Psychiatric Medications","Inclusion Criteria:\n\n* Pregnant women\n* Age 18-45\n* Subjects will be willing to participate over the phone\n* Subjects will be able to provide informed consent\n\nExclusion Criteria:\n\n* Women who have completed their pregnancy\n* Women who are planning to become pregnant\n* Women who are not taking any psychiatric medications and\u002For have no history of psychiatric illness",{"count":423,"type":22},"15 Months","The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics that many people take during pregnancy to treat a wide range of mood, anxiety, executive function, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy, as current data is limited.",[30,516],"Psychotropic Drugs",[97,518,519,520,521,522,523],"Medication use during pregnancy","Psychiatric medications","ADHD","Atypical Antipsychotics","Antidepressants","Sedative Hypnotics","2025-10-22",{"date":526,"type":41},"2025-10-24",{"date":528,"type":41},"2008-11",{"date":530,"type":22},"2033-12",{"name":532,"class":48},"Massachusetts General Hospital",{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":116,"sex":17,"minAge":18,"maxAge":540,"enrollmentInfo":541,"targetDuration":4,"studyType":23,"phases":542,"briefSummary":543,"conditions":544,"keywords":545,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":554,"leadSponsor":556,"locationsCount":49},"100608252","the-effect-of-haptonomy-practice-on-body-functionality-appreciation-and-childbirth-self-efficacy-in-pregnant-women-100608252","NCT07199140","The Effect of Haptonomy Practice on Body Functionality Appreciation and Childbirth Self-Efficacy in Pregnant Women","HAP-Func-Eff","Inclusion Criteria:\n\n* Aged 18 years or older\n* Spontaneous pregnancy at 28 weeks of gestation\n* Primiparous (first pregnancy)\n* Able to read and write in Turkish\n* Healthy singleton pregnancy\n\nExclusion Criteria:\n\n* Any health problems in the mother or fetus\n* History of complications during pregnancy\n* Diagnosed psychiatric disorders or use of psychiatric medication\n* Any physical, mental, or cognitive disabilities","50 Years",{"count":269,"type":22},[25],"Study Type and Aim:\n\nThis clinical study aims to examine the effects of haptonomy practices on appreciation of bodily functionality and childbirth self-efficacy among healthy pregnant women. The study seeks to determine whether haptonomy can enhance these two outcomes.\n\nKey Research Questions:\n\nDo haptonomy practices increase appreciation of bodily functionality in pregnant women? Do haptonomy practices increase childbirth self-efficacy in pregnant women?\n\nComparison:\n\nResearchers will compare an intervention group receiving haptonomy sessions with a control group receiving only routine prenatal care to evaluate the effects of the intervention.\n\nParticipants will:\n\nParticipants will provide written informed consent to take part in the study. Pregnant women in the intervention group will attend four haptonomy sessions, each lasting approximately 45 minutes and held at 7-day intervals. Sessions will include practices to enhance body awareness, relaxation techniques, connecting with the baby, and affirmations supporting bodily functionality and childbirth self-efficacy.\n\nPregnant women in the control group will receive routine prenatal care and follow-up only.\n\nAll participants will complete pretest and posttest measures assessing appreciation of bodily functionality and childbirth self-efficacy.\n\nKeywords: Haptonomy, Vaginal birth, Pregnancy, Prenatal care, Body functionality appreciation, Birth self-efficacy",[30],[266,97,546,547,548,549],"Body functionality appreciation","Vaginal birth","Prenatal care","Birth self-efficacy","2025-09-22",{"date":552,"type":41},"2025-09-30",{"date":497,"type":22},{"date":555,"type":22},"2026-06-15",{"name":557,"class":48},"Tokat Gaziosmanpasa University",{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":23,"phases":567,"briefSummary":568,"conditions":569,"keywords":574,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":589,"locationsCount":49},"100599408","effectiveness-of-a-psychosocial-support-intervention-for-women-diagnosed-with-fetal-anomaly-100599408","NCT07084103","Effectiveness of a Psychosocial Support Intervention for Women Diagnosed With Fetal Anomaly","Effectiveness of a Psychosocial Support Intervention for Women Diagnosed With Fetal Anomaly: Randomised Controlled Trial","Inclusion Criteria:\n\n* In her current pregnancy, the results of the dual or triple screening test (a screening test result of 1:50 or 1:100 is considered a high risk for Down syndrome (Şirin, 2020) and\u002For ultrasound findings (physical\u002Fanatomical and congenital anomalies) indicate a high risk of foetal abnormalities,\n* Decision to continue the pregnancy,\n* Being over 18 years of age,\n* Having received hospital services at least once after the initial diagnosis (this criterion was added to enable the pregnant woman to evaluate the services she received from the hospital after the diagnosis and to express her expectations beyond the services provided)\n* No mental or psychological disorders that would make it difficult to express oneself,\n* Voluntary participation in the study.\n\nExclusion Criteria:\n\n• Pregnant women who do not meet the inclusion criteria will be excluded from the sample.",{"count":566,"type":22},64,[25],"This study aims to evaluate the effectiveness of a psychosocial support intervention for women diagnosed with fetal anomaly. A randomized controlled trial design will be used, and women diagnosed with fetal anomaly will be included as participants. The intervention group will receive a structured psychosocial support program, while the control group will receive routine care.",[570,571,30,572,573],"Fetal Diseases","Congenital Abnormalities","Psychosocial Support Systems","Mental Health",[575,576,577,578,69,579,580,581,582],"Fetal anomaly","Congenital abnormalities","Psychosocial support","Psychological intervention","Prenatal diagnosis","Mental health","Coping strategies","Emotional well-being","2025-07-16",{"date":585,"type":41},"2025-07-24",{"date":587,"type":41},"2025-04-01",{"date":253,"type":22},{"name":590,"class":48},"Sakarya University",{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":116,"sex":17,"minAge":598,"maxAge":57,"enrollmentInfo":599,"targetDuration":4,"studyType":23,"phases":601,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":49},"100597459","development-of-post-disaster-care-protocol-for-pregnant-women-and-evaluation-of-its-effectiveness-100597459","NCT07058766","Development of Post-Disaster Care Protocol for Pregnant Women and Evaluation of Its Effectiveness","Development of Post-Disaster Care Protocol for Pregnant Women and Evaluation of Its Effectiveness: Hatay, Narlıca Sample","Inclusion Criteria:\n\n* Over the age of 18,\n* Positive (+) pregnancy,\n* Able to read and write Turkish and speak and understand Turkish,\n* No mental or psychological disorder that would cause difficulty in expressing oneself,\n* Not receiving a score between 20-27 (severe depression) on HSA-9,\n* No chronic disease or high-risk pregnancy diagnosis requiring hospitalization and follow-up,\n* Volunteer to participate in the study\n\nExclusion Criteria:\n\n* Under 18 years of age,\n* Foreign nationals who cannot read or write Turkish and are inadequate in speaking or understanding Turkish,\n* Those with any mental or psychological disorder\u002Fdiagnosis,\n* Those who score between 20-27 (severe depression) on HSA-9,\n* Those with a chronic disease or a diagnosis of high-risk pregnancy requiring hospitalization and follow-up,\n* Those who do not agree to participate in the study","19 Years",{"count":600,"type":22},43,[25],"It was designed as a randomized controlled experimental study to determine whether the care protocol planned for pregnant women in the disaster area positively affects their physical and psychological health.",[604,30,605],"Earthquake","Support","2025-06-30",{"date":608,"type":41},"2025-07-10",{"date":610,"type":41},"2025-03-09",{"date":612,"type":22},"2026-03-15",{"name":590,"class":48},{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":622,"targetDuration":4,"studyType":23,"phases":624,"briefSummary":625,"conditions":626,"keywords":629,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":4},"100596170","pregfit-adventure-strengthening-mothers-to-be-pregfit-100596170","NCT07041970","PregFit Adventure: Strengthening Mothers-to-Be (PregFit)","PregFit Adventure: Strengthening Mothers-to-Be","PregFit","Inclusion Criteria:\n\n* Pregnant women at low obstetric risk and with no musculoskeletal or health problems affecting their physical condition, ability to exercise or participate in the exergame activities.\n* Read the information sheet and sign the informed consent form to agree to take part in the study.\n* \\>18 years of age\n* Spanish comprehension and communication skills\n* Able to perform physical activity related to the use of the device for at least 30 minutes, 2-3 times a week, for at least 8 weeks\n\nExclusion Criteria:\n\n* Failure to meet any of the inclusion criteria\n* Giving birth during the procedure and at least 8 weeks of device use have not elapsed.",{"count":623,"type":22},84,[25],"1. Design.\n\n   This will be a randomized clinical trial (RCT) with two groups, an experimental or intervention group and a control group.\n2. Population, criteria, sample, calculation.\n\n   The study population will be low-risk pregnant women.\n\n   Inclusion criteria:\n   * Pregnant women at low obstetric risk and with no musculoskeletal or health problems affecting their physical condition, ability to exercise or participate in the exergame activities.\n   * Read the information sheet and sign the informed consent form to agree to take part in the study.\n   * \\>18 years of age\n   * Spanish comprehension and communication skills\n   * Able to perform physical activity related to the use of the device for at least 30 minutes, 2-3 times a week, for at least 8 weeks\n\n   Exclusion criteria:\n   * Failure to meet any of the inclusion criteria\n   * Giving birth during the procedure and at least 8 weeks of device use have not elapsed.\n\n   Assignment: All women receiving maternal education from all participating health centers will be randomized to ensure that there is no sample contamination and their relevance to the intervention or control group will be established according to randomization.\n\n   Sample size calculation: It was estimated that the number of participants should be at least 15% for this pilot study of what would be a future intervention project. Using self-perceived physical fitness as the dependent variable, and in validation studies having had samples of around 160 women (Romero-Gallardo et al., 2020), at least 24 women will be needed in the single intervention group for this pilot study. Similarly, at least 24 women in the control group are needed for comparison. It is estimated that 20% of women may drop out of the intervention before the minimum 8 weeks, thus establishing a sample size of at least 30 women to recruit. Using similar studies (Tuan et al., 2024) as a reference, we will try to reach the ideal sample size of 42 healthy pregnant women who complete the intervention and at least 42 for the control group who receive routine pregnancy follow-up EpS and antenatal classes.\n3. Description of the intervention.\n\n   * Intervention Group: The program consists of using the device, a minimum of 30 minutes per session two to three times per week and not exceeding ≥3 hours, for at least 8 weeks up to a maximum of 3 months or until the onset of discomfort disabling physical activity, with the minimum time for intervention being at least 8 weeks. Exercise based on exergames will be performed including at least 10 minutes of warm-up and 10 minutes of cool-down, and under the supervision of a licensed health professional.\n\nThe training program will focus on strength and functional movements. It requires a Nintendo Switch console, a Ring-Con (a Pilates ring that the user holds or ring holder), wireless Joy-Con controllers (the right Joy-Con, connected to the Ring-Con; and the left Joy-Con, attached to the strap around the player's thigh) and a screen. In adventure mode, women will move through the game by performing physical activities such as jogging or doing squats. To minimize risk, knee-assist mode will be used, which makes the game more accessible. Activating knee assist mode provides support when women perform exercises that require walking, kneeling or squatting, making these activities easier for pregnant women, increasing the fitness benefits of the game. In battle mode women will perform aerobic activities, strength training and yoga exercises that involve the whole body to advance in the game. Women will receive in-game coin rewards, character customization and level progression based on exercise volume, which encourages improvement of their skills. As an example, with the assisted knee mode, women will have to squeeze and stretch the titular ring working muscles such as the trapezius, triceps, pectoralis major and minor and abdominal muscles. In addition, to go about defeating the monsters they will have to do shoulder abduction and adduction exercises, internal and external rotation of the shoulders and flexion of the elbow as shown in the images of the orientation trailer, provided to women and available in this memory.\n\n@Control Group: Low-risk pregnant women who have normal pregnancy follow-up with Health Education received in childbirth preparation classes and maternal education received in routine pregnancy care by primary and specialized care midwives.\n\nMasking: Unique (Results Evaluator).\n\nDescription of masking: Due to the design of the study and the nature of the interventions, it is impossible to mask staff and participants at the care centers. The evaluators, who measure the outcomes, and the interpreter, who analyzes the data, will be masked in this study.\n\nPlace: It will take place in a health center, which is part of the ecosystem of the Andalusian Health Service.",[30,627,628],"Exercise","Game",[179,630,631,632,633,634],"exercise","physical condition","exergames","low-risk pregnancy","physical activity","2025-06-18",{"date":637,"type":41},"2025-06-27",{"date":639,"type":22},"2025-09-01",{"date":641,"type":22},"2026-12-26",{"name":643,"class":48},"University of Jaén",{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":649,"acronym":4,"eligibilityCriteria":650,"healthyVolunteers":116,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":651,"targetDuration":4,"studyType":23,"phases":652,"briefSummary":653,"conditions":654,"keywords":657,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":80},"100589332","effects-of-acupressure-applied-before-cesarean-delivery-on-anxiety-physiological-parameters-and-fetal-heart-rate-100589332","NCT06953037","Effects of Acupressure Applied Before Cesarean Delivery on Anxiety, Physiological Parameters and Fetal Heart Rate","Effects of Acupressure Applied Before Cesarean Delivery on Anxiety, Physiological Parameters and Fetal Heart Rate: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Agree to participate in the study,\n* Be between the ages of 18-45,\n* Have a caesarean section between 37-40 weeks,\n* Not have a risky pregnancy,\n* Have spinal anesthesia,\n\nExclusion Criteria:\n\n* Not having anxiety 1 hour before the cesarean section,\n* Having a risky pregnancy,\n* Having a chronic disease,\n* Having a severe systemic disease,\n* Not receiving spinal anesthesia,\n* Having a body mass index over 25,\n* Having previous acupressure experience,",{"count":566,"type":22},[25],"Cesarean section is the most commonly preferred surgical method in cases where vaginal birth is not possible or complications that may endanger the health of the mother and baby occur. Cesarean section rates are increasing worldwide. According to the latest data (2010-2018) from 154 countries covering 94.5% of live births in the world, 21.1% of women have cesarean section births and it is estimated that this rate will increase to 28.5% by 2030. According to the Centers for Disease Control and Prevention (CDC), the cesarean section rate in the USA, which was 32.1% in 2022, increased to 32.4% in 2023. When the cesarean section rates of the Turkey Demographic Health Survey (TDHS) are examined, the rate, which was 7% in 1993, increased to 52% in 2018, an increase of 45% is observed. In the TRNC, this rate was 11.1% in 1981, but in 2017 this rate increased by an average of 7 times, reaching 72.5%. Pregnant women tend to have cesarean sections because they are affected by the risks that will occur during birth, negative birth stories told among the public, and painful birth scenes seen on social media. Studies have shown that despite the high rates of cesarean sections in pregnant women's birth methods, a significant increase in women's anxiety levels is observed. While waiting for the surgery, pre-operative anxiety, fear of the procedure, etc. are more common than other feelings and symptoms.Studies have also shown that anxiety increases in patient rooms, the night before surgery, and when moving to the operating table. In a study conducted by Lopez, the most important causes of preoperative anxiety were listed as fear of the hospital environment (35%), fear of surgery (33%), fear of anesthesia (45%), and unawareness of the surgery (45%). Concerns about the success of the operation (29.3%), fear of postoperative prognosis (19.5%), and surgical complications (11.4%) are the most common causes of preoperative anxiety. High levels of anxiety experienced before surgery cause increased heart rate, blood pressure, and oxygen consumption during surgery.\n\nControlling and managing preoperative anxiety is one of the most important goals of nursing care worldwide, as in cesarean cases. Mothers need to relax mentally and physically after cesarean sections so that they can care for their babies after birth. A common way to control preoperative anxiety is to use sedatives, but these medications can cause side effects. Therefore, acupressure, which is a non-invasive, low-cost, uncomplicated and non-pharmacological method due to fewer complications, can be used to reduce preoperative anxiety. Acupressure is the application of pressure to stimulate acupoints and meridian lines using an object or fingers, without the use of needles. Acupressure is a simple treatment approach and can be applied by nurses or patients who have received the necessary training, because it is simple and does not require any equipment.",[655,30,656],"Caesarean Section","Anxiety Disorder",[179,658,276,659,660],"caesarean section","fetal heart rate","accupressure","2025-04-29",{"date":663,"type":41},"2025-05-01",{"date":665,"type":22},"2025-05-15",{"date":667,"type":22},"2025-07-05",{"name":669,"class":48},"Eastern Mediterranean University"]